The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Cancer stem cells are critical for cancer initiation, development, and treatment resistance.
Our understanding of these processes, and how they relate to glioblastoma heterogeneity, is …

Combining whole exome sequencing, transcriptome profiling, and T cell repertoire analysis,
we investigate the spatial features of surgically-removed biopsies from multiple loci in tumor …

Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today. Here
we investigate tissue-wide gene expression heterogeneity throughout a multifocal prostate …

Study of the origin and development of cerebellar tumours has been hampered by the
complexity and heterogeneity of cerebellar cells that change over the course of …

Medulloblastoma, a malignant brain tumour primarily diagnosed during childhood, has
recently been the focus of intensive molecular profiling efforts, profoundly advancing our …

Recurrent medulloblastoma and ependymoma are universally lethal, with no approved
targeted therapies and few candidates presently under clinical evaluation. Nearly all …

Chromosome segregation errors cause aneuploidy and genomic heterogeneity, which are
hallmarks of cancer in humans. A persistent high frequency of these errors (chromosomal …

The molecular characterisation of medulloblastoma, the most common paediatric brain
tumour, is crucial for the correct management and treatment of this heterogenous disease …